Alterola Biotech, Inc., a pharmaceutical company, engages in the development of cannabinoid and cannabinoid-like molecules. It focuses on the development of regulated human and animal health pharmaceuticals and regulated food products; production of active pharmaceutical ingredients and food-grade ingredients; and formulation and drug delivery for improved bioavailability, solubility, and stability. Alterola Biotech, Inc. was founded in 2021 and is based in Birkenhead, the United Kingdom.
Stock data | 2023 | Change |
---|---|---|
Price | $0.0081 | N/A |
Market Cap | $6.53M | N/A |
Shares Outstanding | 806.33M | 4.72% |
Employees | 0 | N/A |
Shareholder Equity | 10.10M | -7.60% |
Valuation | 2023 | Change |
---|---|---|
P/E Ratio | -3.75 | N/A |
P/B Ratio | 0.65 | N/A |
Growth | 2023 | Change |
---|---|---|
Return on Equity | -0.1528 | N/A |
Earnings | 2023 | Change |
---|---|---|
Revenue | $0 | N/A |
Earnings | -$1.54M | N/A |
EPS | -0.0022 | N/A |
Earnings Yield | -0.2668 | N/A |
Financial Strength | 2023 | Change |
---|---|---|
Total Assets | $12.38M | N/A |
Total Debt | $1.41M | N/A |
Cash on Hand | $8.89K | N/A |
Debt to Equity | 0.2260 | 105.47% |
Cash to Debt | 0.0063 | -97.41% |
Current Ratio | 0.1115 | -9.59% |